Quarterly ResultMay 20, 2026, 05:02 PM
BiomX Reports Q1 Net Loss $19.14M; Warns on Going Concern
AI Summary
BiomX Inc. reported a net loss of $19,140K for the first quarter of 2026, a significant increase from $7,659K in the same period last year, and an accumulated deficit of $236,036K as of March 31, 2026. The company issued a going concern warning, stating that current funds and expected revenues will only be sufficient for the next several months. This financial update follows a strategic transition to defense, security, and critical infrastructure technology markets, including the deconsolidation of its former biopharmaceutical subsidiary, BiomX Israel, due to insolvency proceedings.
Key Highlights
- Net loss for Q1 2026 was $19,140K, up from $7,659K in Q1 2025.
- Accumulated deficit reached $236,036K as of March 31, 2026.
- Cash and cash equivalents decreased to $1,168K by March 31, 2026.
- Total current assets were $3,043K, down from $5,575K at Dec 31, 2025.
- Total current liabilities decreased to $2,447K from $6,379K at Dec 31, 2025.
- Net cash used in operating activities was $(5,414)K for Q1 2026.
- Company transitioned strategic focus to defense, security, and critical infrastructure.
- Deconsolidated BiomX Israel due to insolvency, recognizing a $1,860K gain.
Price Impact
More from PHGE